Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.

Published

Journal Article

Background: Mutations in the androgen receptor (AR) ligand-binding domain (LBD), such as F877L and T878A, have been associated with resistance to next-generation AR-directed therapies. ARN-509-001 was a phase I/II study that evaluated apalutamide activity in castration-resistant prostate cancer (CRPC). Here, we evaluated the type and frequency of 11 relevant AR-LBD mutations in apalutamide-treated CRPC patients. Patients and methods: Blood samples from men with nonmetastatic CRPC (nmCRPC) and metastatic CRPC (mCRPC) pre- or post-abiraterone acetate and prednisone (AAP) treatment (≥6 months' exposure) were evaluated at baseline and disease progression in trial ARN-509-001. Mutations were detected in circulating tumor DNA using a digital polymerase chain reaction-based method known as BEAMing (beads, emulsification, amplification and magnetics) (Sysmex Inostics' GmbH). Results: Of the 97 total patients, 51 had nmCRPC, 25 had AAP-naïve mCRPC, and 21 had post-AAP mCRPC. Ninety-three were assessable for the mutation analysis at baseline and 82 of the 93 at progression. The overall frequency of detected AR mutations at baseline was 7/93 (7.5%) and at progression was 6/82 (7.3%). Three of the 82 (3.7%) mCRPC patients (2 AAP-naïve and 1 post-AAP) acquired AR F877L during apalutamide treatment. At baseline, 3 of the 93 (3.2%) post-AAP patients had detectable AR T878A, which was lost after apalutamide treatment in 1 patient who continued apalutamide treatment for 12 months. Conclusions: The overall frequency of detected mutations at baseline (7.5%) and progression (7.3%) using the sensitive BEAMing assay was low, suggesting that, based on this assay, AR-LBD mutations such as F877L and T878A are not common contributors to de novo or acquired resistance to apalutamide. ClinicalTrials.gov identifier: NCT01171898.

Full Text

Duke Authors

Cited Authors

  • Rathkopf, DE; Smith, MR; Ryan, CJ; Berry, WR; Shore, ND; Liu, G; Higano, CS; Alumkal, JJ; Hauke, R; Tutrone, RF; Saleh, M; Chow Maneval, E; Thomas, S; Ricci, DS; Yu, MK; de Boer, CJ; Trinh, A; Kheoh, T; Bandekar, R; Scher, HI; Antonarakis, ES

Published Date

  • September 1, 2017

Published In

Volume / Issue

  • 28 / 9

Start / End Page

  • 2264 - 2271

PubMed ID

  • 28633425

Pubmed Central ID

  • 28633425

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdx283

Language

  • eng

Conference Location

  • England